The interleukin 4 promoter polymorphism À589 C/T (rs2243250) was genotyped in 869 multiple sclerosis (MS) patients and 595 healthy blood donors. Sex-specific MS association was evident whereas two flanking polymorphisms showed insignificant P values. In dual luciferase assays of cultured Jurkat cells the cloned promoter comprising the À589 T allele leads to higher expression as compared to the respective construct with the C allele. Together these findings may be discussed functionally as contributing to the genetic predisposition and to the pathogenesis in MS.
Introduction
Multiple sclerosis (MS) is a common neuroinflammatory disease with neurodegenerative aspects leading to demyelination in the central nervous system. 1 Complex interplays of environment and genetic factors are likely causes for disease development. 2 Yet, it is unclear why women are usually affected more frequently than men. In different populations the only virtually consistent MS susceptibility factor comprised of the HLA-DRB1 region. Recent studies point to complex allelic interaction of the HLA-DRB1 locus 3 underscoring possible (auto-) immune mechanisms in the pathogenesis of MS. Inflammatory processes based on autoimmune reactions involving certain human leukocyte antigen molecules imply complex regulatory networks of the immune response. Among others, interleukin 4 (IL4) acts as a regulator to counter-play the inflammatory immune processes. 4 Usually, IL4 is secreted by lymphocytes of the Th2 lineage, 5 whereas the IL4 locus appears silenced in Th1 cells. Because of its immune response regulating role, IL4 is an obvious candidate gene for potential association in MS. We focus here on the IL4 promoter polymorphism À589C/T, since numerous studies have shown association of this single nucleotide polymorphism (SNP) with various inflammatory diseases, including asthma, atopy, brucellosis and rheumatoid arthritis, [6] [7] [8] [9] [10] [11] and because earlier deletion expression assays hinted to a functional role of this SNP. 12 Genotyping two neighbouring polymorphisms revealed that exclusively SNP À589 C/T is associated significantly with MS. In vitro dual luciferase assays were performed to evidence any functional relevance of SNP À589 C/T.
Results and discussion
Here we genotyped the À589 C/T exchange of the IL4 gene in MS patients and controls based on its potential relevance shown in other association studies of (auto-) inflammatory diseases. [6] [7] [8] [9] [10] [11] Screening of this SNP in 869 MS patients and 595 controls demonstrated this sequence variation to be associated with MS (see Table 1 ). Genotyping of two flanking SNPs (rs2243248 and rs2070874) revealed that exclusively the À589 C allele is associated with MS (see Table 1 ). Detailed analyses with regard to disease course and sex show different genotype and allele frequencies in female patients compared to female controls for the associated SNP rs2253250. Further subcategorization reveals that the association is mainly due to female MS patients with chronic disease progression ( Table 1) . Alignment of the SNP and the surrounding sequence with FastSNP 18 revealed a predictable risk for loss of a SOX-5 transcription factor binding site in the C allele. Thus this exchange may herald functional consequences.
The IL4 locus appears actively expressed in Th2 but silenced in Th1 cells. 5, 19 Jurkat cells were used here in expression studies to establish Th lineage conditions as shown previously. [20] [21] [22] Th2-like expression profiles were induced by addition of hrIL4 and a-INFg to the cell culture and Th1-like conditions by tumor necrosis factora addition, respectively. [23] [24] [25] [26] [27] Cells without stimulation were used as control. IL4-stimulated Jurkat cells showed significantly different levels of luminescence for the tested constructs, with the T variation exceeding the intensity of the C allele (Statistical Product and Service Solutions (SPSS)-Tukey test, Po0.05) as well as the vector without insert (SPSS-Tukey test, Po0.002) (see Figure 1 ).
Differences for the C variation versus no insert were not significant. For unstimulated and tumor necrosis factora-stimulated Jurkat cells expression differences were also not significant, albeit slightly higher luminescence levels for the T allele may hint at suboptimal tumor necrosis factor-a stimulation or a basic expression level of factors by Jurkat cells themselves, which promote increased expression of the firefly luciferase when carrying the T insert, respectively ( Figure 1 ). Transfection efficiencies of both constructs were additionally tested by quantitative real-time PCR and revealed no marked differences (data not shown).
This expression difference appears more meaningful since the C allele of this promoter SNP is associated with [14] [15] [16] [17] Informed consent had been obtained from all patients and controls. Research on human genomic material for MS was approved by the ethics commission of the medical faculty of the Ruhr University Bochum, Germany. In addition, this study adhered to the tenets of the Declaration of Helsinki. PCR of the three investigated SNPs was performed using the following oligonucleotides: rs2243248 F: GGGTCCTTACGTTCACTGC; R: TCATCTCAAATTCCTGGGC; rs2243250 F:CCTCACCTGATACGACCTGTC; R: CCGAATTTG TTGTAATGCAGT; rs2070874 F: GTAAAACGACGGCCAGTACCTGTTTGTGAGGCATTTTT; R:CAGGAAACAGCTATGACAATAGGTGTC GATTTG CAGTG. Amplificates were restriction enzyme-digested [BfmI (rs2243248), BsmFI (rs2243250) and Alw26I (rs2070874)] and electrophoresed using 2.5% agarose gels with subsequent ethidium bromide staining. Statistical analyses were performed by w 2 tests with significance levels of Po0.017 (o0.05 as corrected by a factor of 3 for three comparisons, Bonferroni). Hardy-Weinberg equilibrium was tested for all SNP and cohorts. Statistical power was evaluated assuming a small effect size of 0.20 of the variation, a ¼ 0.05 and two degrees of freedom by gpower software. Power calculated under the assumption of a small effect size of 0.20 of the variation, a ¼ 0.05 and two degrees of freedom by gpower software. 13 MS in female patients with chronic disease progression ( Table 1 ). The homozygous CC genotype represents a risk factor for female MS patients that causes decreased anti-inflammatory cytokine production presumably leading to prolonged inflammatory phases. These data comply with earlier findings of association between increased IL4 production and a certain promoter/exon haplotype in Japanese patients. 28 The À589 C/T variation itself-and not flanking sequence variations-has functional relevance in the transcriptional regulation of IL4 expression in Th2 lineage cells. Dependent on the immunological situation, the À589 C/T variation may contribute to susceptibility for several autoimmune diseases by varying IL4 expression levels and hence modulation of the anti-inflammatory downregulation. Differential susceptibilities for certain autoimmune diseases might be reflected in different IL4 À589 C/T-allele distribution patterns in various populations. Statistical analyses performed to detect non-randomness in allele distribution allocate selective advantages of the À589 C/T spreading when compared to other SNPs in different populations. 29, 30 Therefore our association result has to be replicated in an independent cohort to verify that this promoter polymorphism represents a major risk factor for MS like for other inflammatory diseases under certain environmental influences. A BglII restriction site is present within the R-and a constructed SacI restriction site within the F-primer sequence (modified nucleotide underlined). Respective fragments were isolated from DNAs of homozygously genotyped patients. The regions of interest have been re-sequenced after amplification, thus excluding additional genomic variations other than the relevant SNP À589 C/T. Each variation was ligated into the pGL3-promoter vector (Promega, Mannheim, Germany) using the SacI and BglII restriction sites. The constructs were separately transfected into TOP10 Eschericha coli cells via electroporation. The vectors were re-sequenced after purification to verify respective sequence contents. Three different constructs (pGL3 promoter vector with the T allele comprising fragment, the one with the C allele or with no insert, respectively) were transfected separately. Each transfection into Jurkat cells included the pGL4.74[hRluc/TK] vector (Promega) for normalization using the X-tremeGENE Q2 transfection reagent (Roche, Mannheim, Germany). Transfections were optimized according to the respective manual. At 48 h after transfection, each reaction batch was diluted to an end concentration of 8 Â 10 5 cells/ml and transferred into new medium (Iscove þ 200 mM glutamine, þ 1% Pen/Strep) with subsequent cytokine treatment. Th2 stimulation was achieved by addition of 30 ng/ml human recombinant IL4, 10 mg/ml anti-interferon g (a-INFg) and 10 mg/ml anti-interleukin 12. Th1 stimulation was performed by the addition of 30 ng/ml tumor necrosis factor-a. All cytokines were purchased from Peprotech (London, UK). After 24 h IL4 promoter expression levels were measured using the Dual-Luciferase reporter assay system. Assays were performed in triplicate in three independent experiments with the exception of the assays lacking stimulation (two experiments). The luminescence signal of the firefly luciferase was normalized according to the luminescence signal of the coexpressed renilla luciferase. Normalized C-and T-allele signals were compared to normalized signals of pGl3 vectors without insert.
